Streetbeat News

Analyst Ratings

DBRG

JP Morgan has upgraded DigitalBridge (DBRG) from Neutral to Overweight and raised its price target from $19 to $25. This has resulted in DigitalBridge shares trading higher.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:39 pm

AYRWF

VRNOF

Cannabis industry leaders shared their strategies for success without relying on the SAFE Banking Act at the 2024 Benzinga Cannabis Capital Conference. Darren Weiss, president of Verano Holdings Corp (OTCQX:VRNOF), emphasized building a sustainable business without assuming cash availability. Jamie Mendola from Ayr Wellness (OTCQX:AYRWF) noted a slight improvement in risk appetite in the sector. Alex Gray from Good Day Farm suggested that capital will be more readily available once either SAFER or rescheduling happens. The leaders advised focusing on core markets, staying lean, and building a business that can stand on its own.

Portfolio Pulse from Nina Zdinjak

September 28, 2023 | 12:36 pm

HUN

Wells Fargo analyst Michael Sison has maintained an Equal-Weight rating on Huntsman (NYSE:HUN) and lowered the price target from $29 to $25.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:36 pm

UNFI

Goldman Sachs analyst Leah Jordan has maintained a Neutral rating on United Natural Foods (NYSE:UNFI) and lowered the price target from $24 to $15.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:34 pm

NEP

BMO Capital analyst James Thalacker has maintained an 'Outperform' rating on NextEra Energy Partners (NEP) but lowered the price target from $76 to $47.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:33 pm

QTRX

Goldman Sachs analyst Matthew Sykes has maintained a 'Buy' rating on Quanterix (NASDAQ:QTRX) and raised the price target from $30 to $34.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:33 pm

NEE

BMO Capital analyst James Thalacker has maintained an 'Outperform' rating on NextEra Energy (NYSE:NEE) but lowered the price target from $88 to $72.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:32 pm

MORF

BMO Capital analyst Evan David Seigerman maintains an Outperform rating on Morphic Holding (NASDAQ:MORF) but has lowered the price target from $106 to $52.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:29 pm

LMND

BMO Capital's analyst Michael Zaremski has maintained an 'Underperform' rating on Lemonade (NYSE:LMND) and raised the price target from $8 to $9.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 12:27 pm

LLY

NVO

Prescriptions for diabetes and obesity drugs like Ozempic and Wegovy have surged 300% from early 2020 to the end of 2022, according to an analysis by Trilliant Health. Novo Nordisk's Ozempic accounted for over 65% of total prescriptions. Eli Lilly's Mounjaro and Novo Nordisk's Saxenda have also been prescribed. The surge can be attributed to their ability to induce significant weight loss. However, future prescription volumes depend on resolving supply shortages faced by Novo Nordisk and Eli Lilly in the U.S.

Portfolio Pulse from Vandana Singh

September 28, 2023 | 12:22 pm